Molecular targets in protein misfolding and neurodegenerative disease /

Aimed at "drug discoverers"--I.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular - the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, d...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Seneci, Pierfausto (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London : Academic Press, 2015.
Temas:
Molecular neurobiology.
Nervous system > Diseases.
Tauopathies > drug therapy
Tauopathies > etiology
Nervous System Diseases
Molecular Targeted Therapy > methods
Protein Folding > drug effects
Neurobiologie mol�eculaire.
Syst�eme nerveux > Maladies.
SCIENCE > Life Sciences > Zoology > General.
Molecular neurobiology
Nervous system > Diseases
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover; Title Page; Copyright Page; Dedication; Contents; Abbreviations; Chapter 1
  • Protein Misfolding, Neurodegeneration and Tau; 1.1
  • The neurodegeneration scenario; 1.2
  • Protein folding: physiological benefits and pathological consequences; 1.3
  • Tau: An intrinsically disordered, flexible, and aggregation-prone protein; 1.4
  • Tauopathies: Aggregation-prone tau in neurodegenerative disease (NDD); 1.4.1
  • Class 0 Tauopathies; 1.4.2
  • Class I Tauopathies; 1.4.3
  • Class II Tauopathies; 1.4.4
  • Class III Tauopathies; 1.4.5
  • Class IV Tauopathies; 1.4.6
  • Tau Mutations; References.
  • Chapter 2
  • Targeting the Protein Quality Control (PQC) Machinery2.1
  • Molecular chaperones, PQC, and neurodegeneration; 2.2
  • Molecular targets; 2.2.1
  • Hsp27; 2.2.2
  • Hsp70; 2.2.3
  • Hsp90; 2.3
  • Disease-modifying compounds; References; Chapter 3
  • Proteasomal Degradation of Soluble, Misfolded Proteins; 3.1
  • UPS-mediated degradation of misfolded proteins; 3.2
  • UPS-mediated degradation of misfolded proteins in NDDs; 3.3
  • UPS-targets; 3.3.1
  • CHIP; 3.3.2
  • USP14; 3.4
  • Disease-modifying compounds; References; Chapter 4
  • Unselective Disposal of Cellular Aggregates.
  • 4.1
  • Autophagy-mediated degradation of protein aggregates4.2
  • Autophagy-mediated degradation of protein aggregates in NDDs; 4.3
  • Macroautophagy-targets; 4.3.1
  • mTORC1; 4.4
  • Disease-modifying compounds; References; Chapter 5
  • Selective Disposal of Insoluble Protein Aggregates; 5.1
  • Aggrephagy-mediated degradation of protein aggregates; 5.2
  • Selective autophagy-mediated degradation of protein aggregates in NDDs; 5.3
  • Selective autophagy-targets; 5.3.1
  • p62; 5.3.2
  • HDAC6; 5.4
  • Disease-modifying compounds; References; Chapter 6
  • Assembly and Disassembly of Protein Aggregates.
  • 6.1
  • Introduction6.2
  • Disordered protein aggregates and ordered amyloid fibrils; 6.2.1
  • The Target: Interfering with (Neuro)toxic Tau Species in the Aggregation Process; 6.3
  • Chaperone-driven disaggregation of protein aggregates; 6.3.1
  • The Target: Hsp110; 6.4
  • Disease-modifying compounds; References; Conclusions; Index.

Ejemplares similares